Overactive Bladder Treatment Market Size, Share, And Growth Report 2032
Overactive Bladder Treatment Market By Pharmacotherapy (Anticholinergic, Botox, and Others), By Disease (Neurogenic Overactive Bladder and Idiopathic Overactive Bladder), and By Region - Global And Regional Industry Overview, market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2024-2032
| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 3.68 Billion | USD 5.72 Billion | 5.04% | 2023 |
Table Of Content
- Chapter 1. Preface
- 1.1. Report Description and Scope
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
- Chapter 2. Executive Summary
- 2.1. Overactive bladder treatment Market, 2016-2025 (USD Million)
- 2.2. Overactive bladder treatment Market: Market Snapshot
- Chapter 3. Overactive Bladder Treatment Market - Industry Analysis
- 3.1. Overactive Bladder Treatment Market: Dynamics
- 3.2. Market Drivers
- 3.2.1. Growing prevalence of overactive bladder
- 3.2.2. Growing geriatric population
- 3.2.3. Rising neurological disorders
- 3.2.4. Increasing government initiatives and awareness in developing nations
- 3.2.5. Advanced R&D in the field of overactive bladder treatment
- 3.2.6. Rising acute urinary tract infection cases
- 3.3. Restraints
- 3.3.1. Lack of awareness in underdeveloped nations
- 3.3.2. Undesirable effects of current treatments
- 3.4. Opportunity
- 3.4.1. Evolving market
- 3.4.2. Advanced technology
- 3.5. Porter's Five Forces Analysis
- 3.6. Market Attractiveness Analysis
- 3.6.1. Market attractiveness analysis by pharmacotherapy
- 3.6.2. Market attractiveness analysis by disease
- 3.6.3. Market attractiveness analysis by region
- Chapter 4. Overactive Bladder Treatment Market - Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global overactive bladder treatment market: company market share, 2018
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New product launches
- 4.2.3. Agreements, partnerships, collaborations, and joint ventures
- 4.2.4. Research and development and regional expansion
- 4.3. Price trend analysis
- 4.1. Company market share analysis
- Chapter 5. Global Overactive Bladder Treatment Market - Pharmacotherapy Analysis
- 5.1. Global overactive bladder treatment market overview: by pharmacotherapy
- 5.1.1. Global overactive bladder treatment market share, by pharmacotherapy, 2018 and 2025
- 5.2. Botox
- 5.2.1. Global overactive bladder treatment market by botox, 2016-2025 (USD Million)
- 5.3. Anticholinergic
- 5.3.1. Global overactive bladder treatment market by anticholinergic, 2016-2025 (USD Million)
- 5.4. Others
- 5.4.1. Global overactive bladder treatment market by others, 2016-2025 (USD Million)
- 5.1. Global overactive bladder treatment market overview: by pharmacotherapy
- Chapter 6. Global Overactive Bladder Treatment Market - Disease Analysis
- 6.1. Global overactive bladder treatment market overview: by disease
- 6.1.1. Global overactive bladder treatment market share, by disease, 2018 and 2025
- 6.2. Idiopathic Overactive Bladder
- 6.2.1. Global overactive bladder treatment market by idiopathic overactive bladder, 2016-2025 (USD Million)
- 6.3. Neurogenic Overactive Bladder
- 6.3.1. Global overactive bladder treatment market by neurogenic overactive bladder, 2016-2025 (USD Million)
- 6.1. Global overactive bladder treatment market overview: by disease
- Chapter 7. Global Overactive Bladder Treatment Market - Regional Analysis
- 7.1. Global overactive bladder treatment market overview: by region
- 7.1.1. Global overactive bladder treatment market share, by region, 2018 and 2025
- 7.2. North America
- 7.2.1. North America overactive bladder treatment market, 2016-2025 (USD Million)
- 7.2.2. North America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.2.3. North America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.2.4. The U.S.
- 7.2.4.1. The U.S. overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.2.4.2. The U.S. overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.2.5. Rest of North America
- 7.2.5.1. Rest of North America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.2.5.2. Rest of North America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3. Europe
- 7.3.1. Europe overactive bladder treatment market, 2016-2025 (USD Million)
- 7.3.2. Europe overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.3. Europe overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3.4. The U.K.
- 7.3.4.1. U.K. overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.4.2. U.K. overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3.5. France
- 7.3.5.1. France overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.5.2. France overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3.6. Germany
- 7.3.6.1. Germany overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.6.2. Germany overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.3.7. Rest of Europe
- 7.3.7.1. Rest of Europe overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.3.7.2. Rest of Europe overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific overactive bladder treatment market, 2016-2025 (USD Million)
- 7.4.2. Asia Pacific overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.3. Asia Pacific overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4.4. China
- 7.4.4.1. China overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.4.2. China overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4.5. Japan
- 7.4.5.1. Japan overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.5.2. Japan overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4.6. India
- 7.4.6.1. India overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.6.2. India overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.4.7. Rest of Asia Pacific
- 7.4.7.1. Rest of Asia Pacific overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.4.7.2. Rest of Asia Pacific overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America overactive bladder treatment market, 2016-2025 (USD Million)
- 7.5.2. Latin America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.5.3. Latin America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.5.4. Brazil
- 7.5.4.1. Brazil overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.5.4.2. Brazil overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.5.5. Rest of Latin America
- 7.5.5.1. Rest of Latin America overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.5.5.2. Rest of Latin America overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.6. The Middle East and Africa
- 7.6.1. The Middle East and Africa overactive bladder treatment market, 2016-2025 (USD Million)
- 7.6.2. The Middle East and Africa overactive bladder treatment market revenue, by pharmacotherapy, 2016-2025 (USD Million)
- 7.6.3. The Middle East and Africa overactive bladder treatment market revenue, by disease, 2016-2025 (USD Million)
- 7.1. Global overactive bladder treatment market overview: by region
- Chapter 8. Company Profiles
- 8.1. Macleods Pharmaceuticals
- 8.1.1. Overview
- 8.1.2. Financials
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategy
- 8.1.5. Recent Developments
- 8.2. Allergan
- 8.2.1. overview
- 8.2.2. Financials
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategy
- 8.2.5. Recent Developments
- 8.3. Mylan
- 8.3.1. Overview
- 8.3.2. Financials
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategy
- 8.3.5. Recent Developments
- 8.4. Endo International
- 8.4.1. Overview
- 8.4.2. Financials
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategy
- 8.4.5. Recent Developments
- 8.5. Hisamitsu Pharmaceutical
- 8.5.1. Overview
- 8.5.2. Financials
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategy
- 8.5.5. Recent Developments
- 8.6. Apotex
- 8.6.1. Overview
- 8.6.2. Financials
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategy
- 8.6.5. Recent Developments
- 8.7. Johnson & Johnson
- 8.7.1. Overview
- 8.7.2. Financials
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategy
- 8.7.5. Recent Developments
- 8.8. Aurobindo Pharma
- 8.8.1. Overview
- 8.8.2. Financials
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategy
- 8.8.5. Recent Developments
- 8.9. Medtronic
- 8.9.1. Overview
- 8.9.2. Financials
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategy
- 8.9.5. Recent Developments
- 8.10. Cogentix Medical
- 8.10.1. Overview
- 8.10.2. Financials
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategy
- 8.10.5. Recent Developments
- 8.1. Macleods Pharmaceuticals
Table Of Figures
List of Figures
1. Market Research Process
2. Market Research Methodology
3. Global overactive bladder treatment market, 2016–2025 (USD Million)
4. Porter’s Five Forces Analysis
5. Global overactive bladder treatment market attractiveness, by pharmacotherapy
6. Global overactive bladder treatment market attractiveness, by disease
7. Global overactive bladder treatment market attractiveness, by region
8. Global overactive bladder Treatment Market share, by pharmacotherapy, 2018 and 2025
9. Global overactive bladder treatment market by botox, 2016–2025 (USD Million)
10. Global overactive bladder treatment market by anticholinergic, 2016–2025 (USD Million)
11. Global overactive bladder treatment market by others, 2016–2025 (USD Million)
12. Global overactive bladder treatment market share, by disease, 2018 and 2025
13. Global overactive bladder treatment market by idiopathic overactive bladder, 2016–2025 (USD Million)
14. Global overactive bladder treatment market by neurogenic overactive bladder, 2016–2025 (USD Million)
15. Global overactive bladder treatment market share, by region, 2018 and 2025
16. North America overactive bladder treatment market, 2016–2025 (USD Million)
17. Europe overactive bladder treatment market, 2016–2025 (USD Million)
18. Asia Pacific overactive bladder treatment market, 2016–2025 (USD Million)
19. Latin America overactive bladder treatment market, 2016–2025 (USD Million)
20. The Middle East and Africa overactive bladder treatment market, 2016–2025 (USD Million)
Table Of Tables
List of Tables
1. Global overactive bladder treatment market: snapshot
2. Drivers of the overactive bladder treatment market: impact analysis
3. Restraints of the overactive bladder treatment market: impact analysis
4. North America overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
5. North America overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
6. The U.S. overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
7. The U.S. overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
8. Rest of North America overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
9. Rest of North America overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
10. Europe overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
11. Europe overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
12. U.K. overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
13. U.K. overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
14. France overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
15. France overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
16. Germany overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
17. Germany overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
18. Rest of Europe overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
19. Rest of Europe overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
20. Asia Pacific overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
21. Asia Pacific overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
22. China overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
23. China overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
24. Japan overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
25. Japan overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
26. India overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
27. India overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
28. Rest of Asia Pacific overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
29. Rest of Asia Pacific overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
30. Latin America overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
31. Latin America overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
32. Latin America overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
33. Latin America overactive bladder treatment market revenue, by sample, 2016–2025 (USD Million)
34. Brazil overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
35. Brazil overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
36. Rest of Latin America overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
37. Rest of Latin America overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
38. The Middle East and Africa overactive bladder treatment market revenue, by pharmacotherapy, 2016–2025 (USD Million)
39. The Middle East and Africa overactive bladder treatment market revenue, by disease, 2016–2025 (USD Million)
Methodology
FrequentlyAsked Questions
Overactive bladder is a urological condition associated with urination problems and is also known as overactive bladder syndrome. Major symptoms include urgency in urination and change in urination frequency. It can cause various neurological diseases, such as Parkinson’s disease.
According to study, the Overactive Bladder Treatment Market size was worth around USD 3.68 billion in 2023 and is predicted to grow to around USD 5.72 billion by 2032.
The CAGR value of Overactive Bladder Treatment Market is expected to be around 5.04% during 2024-2032.
North America has been leading the Overactive Bladder Treatment Market and is anticipated to continue on the dominant position in the years to come.
The Overactive Bladder Treatment Market is led by players like Macleods Pharmaceuticals, Allergan, Mylan, Endo International, Sanofi, Apotex, Johnson & Johnson, Aurobindo Pharma, Medtronic, Cogentix Medical, Astellas Pharma, Pfizer, Teva Pharmaceutical, Hisamitsu Pharmaceutical, and Intas Pharmaceuticals.
HappyClients
